Vannucchi AM
Vannucchi AM
Professor of Hematology, University of Florence
Email verificata su
Citata da
Citata da
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J Nangalia, CE Massie, EJ Baxter, FL Nice, G Gundem, DC Wedge, ...
New England Journal of Medicine 369 (25), 2391-2405, 2013
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
C Harrison, JJ Kiladjian, HK Al-Ali, H Gisslinger, R Waltzman, ...
New England Journal of Medicine 366 (9), 787-798, 2012
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
F Cervantes, B Dupriez, A Pereira, F Passamonti, JT Reilly, E Morra, ...
Blood 113 (13), 2895-2901, 2009
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis …
A Tefferi, J Thiele, A Orazi, HM Kvasnicka, T Barbui, CA Hanson, G Barosi, ...
Blood, The Journal of the American Society of Hematology 110 (4), 1092-1097, 2007
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
T Barbui, G Barosi, G Birgegard, F Cervantes, G Finazzi, M Griesshammer, ...
Journal of Clinical Oncology 29 (6), 761, 2011
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and …
F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ...
Blood 115 (9), 1703-1708, 2010
Cardiovascular events and intensity of treatment in polycythemia vera
R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ...
N Engl J Med 368, 22-33, 2013
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
AM Vannucchi, JJ Kiladjian, M Griesshammer, T Masszi, S Durrant, ...
New England Journal of Medicine 372 (5), 426-435, 2015
Mutations and prognosis in primary myelofibrosis
AM Vannucchi, TL Lasho, P Guglielmelli, F Biamonte, A Pardanani, ...
Leukemia 27 (9), 1861-1869, 2013
Clinical profile of homozygous JAK2 617V> F mutation in patients with polycythemia vera or essential thrombocythemia
AM Vannucchi, E Antonioli, P Guglielmelli, A Rambaldi, G Barosi, ...
Blood 110 (3), 840-846, 2007
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ...
Leukemia 27 (9), 1874-1881, 2013
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
A Tefferi, P Guglielmelli, DR Larson, C Finke, EA Wassie, L Pieri, ...
Blood 124 (16), 2507-2513, 2014
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for …
G Barosi, RA Mesa, J Thiele, F Cervantes, PJ Campbell, S Verstovsek, ...
Leukemia 22 (2), 437-438, 2008
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study
T Barbui, J Thiele, F Passamonti, E Rumi, E Boveri, M Ruggeri, ...
Journal of clinical oncology 29 (23), 3179-3184, 2011
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
G Rotunno, C Mannarelli, P Guglielmelli, A Pacilli, A Pancrazzi, L Pieri, ...
Blood 123 (10), 1552-1555, 2014
Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden
AM Vannucchi, E Antonioli, P Guglielmelli, G Longo, A Pancrazzi, ...
Leukemia 21 (9), 1952-1959, 2007
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
F Cervantes, AM Vannucchi, JJ Kiladjian, HK Al-Ali, A Sirulnik, ...
Blood 122 (25), 4047-4053, 2013
Effect of mutation order on myeloproliferative neoplasms
CA Ortmann, DG Kent, J Nangalia, Y Silber, DC Wedge, J Grinfeld, ...
New England Journal of Medicine 372 (7), 601-612, 2015
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
A Carobbio, J Thiele, F Passamonti, E Rumi, M Ruggeri, F Rodeghiero, ...
Blood 117 (22), 5857-5859, 2011
Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment
G Ficarra, F Beninati, I Rubino, A Vannucchi, G Longo, P Tonelli, ...
Journal of clinical periodontology 32 (11), 1123-1128, 2005
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20